Department of Pharmacology, Yamagata University School of Medicine,
990-9585 Yamagata, Japan
We investigated the inotropic effect of SCH00013
(4,5-dihydro-6-[1-[2-hydroxy-2-(4-cyanophenyl)ethyl]-1,2,5,6-tetrahydropyrido-4-yl]pyridazin-3(2H)-one) on isolated dog and rabbit ventricular muscles and in indo-1 loaded rabbit ventricular cardiomyocytes. SCH00013 elicited a positive inotropic effect in a concentration-dependent manner
(10
6 to 10
4 M) in
both species in the presence of bupranolol. The positive inotropic
effects of 10
4 M SCH00013 on the dog and
rabbit were 38% and 29% of the maximal response to isoproterenol.
SCH00013 did not alter the rate of beating in isolated rabbit right
atria. In indo-1 loaded rabbit ventricular cardiomyocytes, SCH00013 at
10
4 M increased the systolic cell shortening
by 52% above the base-line value in association with an insignificant
increase in the systolic fluorescence ratio by 15% above the control.
SCH00013 shifted the relationship between the Ca++
transients and cell shortening to the left as compared with that of
elevation of [Ca++]o. In the dog and rabbit
ventricular muscles, carbachol partially inhibited the positive
inotropic effect of SCH00013. SCH00013 did not affect the positive
inotropic effect of isoproterenol at 3 × 10
6 M, but enhanced it at 3 × 10
5 M. These results indicate that SCH00013
is a cardiotonic agent that primarily acts via an
increase in myofibrillar Ca++ sensitivity with a moderate
contribution of the cAMP-dependent mechanism at higher concentrations.
SCH00013 has no chronotropic activity. The pharmacological profile of
SCH00013 implies that the compound may be a promising cardiotonic agent
for the treatment of congestive heart failure.
 |
Introduction |
Cardiac
glycosides and catecholamines have been used as cardiotonic agents for
the treatment of heart failure. Because these agents have disadvantages
such as narrow safety margin and arrhythmogenicity due to
Ca++ overload, extensive efforts have been
focused on development of novel cardiotonic agents to replace these
classical agents in the treatment of heart failure (Farah et
al., 1984
). Amrinone, milrinone, olprinone, vesnarinone,
pimobendan and denopamine have been developed in the course of such an
effort (Endoh and Hori, 1993
). Although it has been demonstrated that
these agents are effective in improving quality of life of the patients
with heart failure due to improvements of hemodynamic parameters and
exercise capacity, some of them (e.g., amrinone,
milrinone) failed to prolong the life-span of patients but rather
shortened it even compared with placebo (Kinney et al.,
1982
; Likoff et al., 1984
; Packer, 1989
; Packer et
al., 1991
), and the effects of other agents are still
controversial (e.g., vesnarinone) (OPC-8212
Multicenter Research Group, 1990
; Feldman et al., 1993
,
1997
; Scherrer-Crosdie et al., 1997
) or under clinical
investigation (e.g., pimobendan and denopamine)
(Kino et al., 1986
; Takarada et al., 1987
; Kubo et al., 1992
; Sasayama et al., 1994
).
Classical cardiotonic agents act by an increase in intracellular
Ca++ mobilization (Smith et al.,
1984a
, 1984b
; Endoh, 1996
). In the clinical setting, most patients with
congestive heart failure are treated with digitalis and
angiotensin-converting enzyme inhibitors, and/or diuretics, and newly
developed cardiotonic agents have been administered to the patients,
whose hemodynamic parameters did not respond favorably to the classical
pharmacological agents. The fact that digitalis is ineffective might
mean that an increase in intracellular Ca++ ions
is not able to improve the symptom and such a situation may suffer
readily from further facilitation of Ca++
mobilizing process. Because these newly developed agents act primarily
by an increase in intracellular Ca++
mobilization, Ca++ overload could easily occur to
result in harmful effects on the patients with digitalis-resistant
heart failure.
The positive inotropic effects of cardiotonic agents are achieved by an
increase in intracellular free Ca++ concentration
([Ca++]i), by an increase
in the sensitivity of contractile proteins to
Ca++ ions (termed Ca++
sensitizers) or by combinations of the two mechanisms (Blinks and
Endoh, 1986
). Ca++ sensitizers that act through
the latter mechanism do not require an increase in activation energy
that is consumed to increase intracellular Ca++
mobilization and to remove Ca++ ions (Suga,
1990
), and are devoid of arrhythmogenicity and myocardial cell injury
due to intracellular Ca++ overload (Endoh, 1996
).
Therefore, interests in the development of novel
Ca++ sensitizers as cardiotonic agents have been
increasing, but up to now no such agents that primarily act as
Ca++ sensitizers are available for the clinical
application to the patients with chronic heart failure.
We have screened the mechanism of action of a series of pyridazinone
derivatives and chosen SCH00013
(4,5-dihydro-6-[1-[2-hydroxy-2-(4-cyanophenyl)ethyl]-1,2,5,6-tetrahydropyrido-4-yl]pyridazin-3(2H)-one; fig. 1) as a novel cardiotonic agent to
be developed for the treatment of patients with congestive heart
failure. Because the positive force-frequency relationship disappears
or inverted in ventricular myocardium isolated from severe heart
failure (Mulieri et al., 1992
; Schwinger et al.,
1994
), we focused to develop cardiotonic agents with least positive
chronotropic activity. The preliminary experiments indicated that this
compound produces a positive inotropic effect without chronotropic
action. In this study, we carried out experiments to elucidate the
pharmacological profile of cardiac action of this compound. For this
purpose we investigated the inotropic effect of SCH00013 in dog and
rabbit ventricular myocardium and in indo-1 loaded rabbit ventricular
cardiomyocytes. The preliminary accounts of this study have been
published as an abstract (Sugawara and Endoh, 1997
).

View larger version (8K):
[in this window]
[in a new window]
|
Fig. 1.
Chemical structure of SCH00013
(4,5-dihydro-6-[1-[2-hydroxy-2-(4-cyanophenyl)ethyl]-1,2,5,6-tetrahydropyrido-4-yl]pyridazin-3(2H)-one).
|
|
 |
Methods |
Isolation of ventricular trabeculae of the dog and papillary
muscles and right atria of the rabbit.
Mongrel dogs of either sex
(7-12 kg) and male Japanese White rabbits (1.8-2.2 kg) were
anesthetized with sodium pentobarbital (40 mg/kg in dog and 50 mg/kg in
rabbit, i.v.). The right atrium was excised from the rabbit heart and
papillary muscles and ventricular trabeculae were excised from the
right ventricles of the rabbit and the dog, respectively. These muscles
were mounted in 20 ml organ baths containing Krebs-Henseleit solution
(with 0.057 mM ascorbic acid and 0.027 mM disodium EDTA). The
composition of the solution (in mM) was as follows: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 24.9, and glucose 11.1. The solution was
continuously gassed with 95% O2/5%
CO2 at 37°C (pH 7.4). Papillary muscles and
ventricular trabeculae were electrically stimulated by square-wave
pulses of 5 msec duration and a voltage about 20% above the threshold
at 1.0 Hz (rabbit) or 0.5 Hz (dog) through bipolar platinum electrodes.
The isometric tension was detected with strain gauge transducers
(Shinkoh UL-10 GR, Minebea, Tokyo, Japan) and recorded on a thermal
pen-writing oscillograph (RECTI-HORIZ-8K, NEC San-ei Instruments,
Tokyo, Japan). During the equilibration period of 60 min the muscles
were initially stretched under a resting tension of 5 mN and the length
was then adjusted to give 90% of the maximal developed tension. The
inotropic response to drugs was expressed as a percentage of ISOmax in
each preparation. The ISOmax was defined as the maximal force in the presence of isoproterenol minus the basal force of contraction before
the administration of isoproterenol.
The spontaneous rate of beating of right atria was determined by the
number of contractions recorded at a high chart speed (5 mm/sec).
Isolation of rabbit ventricular cardiomyocytes.
Ventricular
cardiomyocytes were obtained by a procedure slightly modified from that
described previously (Fujita and Endoh, 1996
). Briefly, male Japanese
White rabbits (1.8-2.0 kg) were anesthetized with pentobarbital sodium
(40 mg/kg, i.v.) and given heparin (600 units/kg, i.v.). The heart was
rapidly excised, mounted on a Langendorff apparatus and retrogradely
perfused for ~1 min at perfusion pressure of 80 cm
H2O with HEPES-Tyrode solution containing (in
mM): NaCl 136.5, KCl 5.4, MgCl2 0.53, CaCl2 1.2, NaH2PO4 0.33, glucose 5.0, HEPES 5.0; pH 7.4 (adjusted with NaOH). The solution was continuously
gassed with 100% O2 at 37°C. The heart was
then perfused with nominally Ca++-free
HEPES-Tyrode solution for 5 min, followed by perfusion with recirculation of Ca++-free HEPES-Tyrode solution
to which collagenase (0.6 mg/ml) and protease (0.1 mg/ml) had been
added. After approximately 20 min, when the heart became homogeneously
soft, the enzymes were washed out for 1 min by perfusion with
HEPES-Tyrode solution containing 0.2 mM CaCl2.
The ventricles were then removed, minced in HEPES-Tyrode solution
containing 0.2 mM CaCl2, and filtered through a
nylon mesh (200 µm). The myocytes were resuspended in a stepwise
manner in HEPES-Tyrode solution containing 0.2, 0.4, and 0.8 mM
CaCl2. The myocytes were finally resuspended in
HEPES-Tyrode solution containing 1.2 mM CaCl2 and
kept for 1 hr or longer at room temperature (24 to 26°C) before the
loading with the acetoxymethyl ester form of the
Ca++ sensitive fluorescence probe indo-1
(indo-1/AM).
Simultaneous measurements of cell length and
Ca++ transient.
Myocytes were loaded with
indo-1/AM and all the after steps were carried out at room temperature
(24-26°C). The loading solution consisted of 10 µl of 1 mM
indo-1/AM, 40 µl DMSO, 90 µl fetal bovine serum, 10 µl of 20%
pluronic F-127 (wt/wt in DMSO), and 1 ml HEPES-Tyrode solution. The
loading solution described above was sonicated for 3 min and 1 ml of
cell suspension was added to it. The myocytes were allowed to load with
indo-1/AM for 1 to 4 min and then centrifuged at 150 rpm for 1 min. The
supernatant was discarded and the pellet was resuspended in
HEPES-Tyrode solution. The myocytes were placed in a perfusion chamber
on the stage of an inverted microscope (Diaphot TMD 300, Nikon, Tokyo,
Japan) equipped for simultaneous recordings of cell length and indo-1 fluorescence. After 10 min, the myocytes were perfused at a rate of
about 2 ml/min with bicarbonate buffer containing (in mM) NaCl 116.4, KCl 5.4, MgSO4 0.81, CaCl2
1.2, NaH2PO4 1.02, glucose
5.0, NaHCO3 23.8. The buffer was continuously
gassed with 95% O2-5% CO2
(pH 7.4). Bipolar platinum electrodes placed in the perfusion chamber
were used to stimulate the myocytes with square-wave pulses of 5 msec
duration and a voltage of 0.5 to 0.7 V at 0.5 Hz.
Indo-1 fluorescence was excited with the light from a xenon lamp with
wavelength of 355 nm, reflected by a 380 nm long-pass dichroic mirror,
and detected by means of a fluorescence spectrophotometer (CAM-230,
Japan Spectroscopic, Tokyo, Japan). Excitation light was applied to the
myocyte through a neutral density filter to minimize the photobleaching
of indo-1. The emitted fluorescence was collected by an objective lens
(CF Fluor DL40, Nikon) and after passing through the 380 nm long-pass
dichroic mirror, it was first separated by a 580 nm long-pass dichroic
mirror (Omega Optical, Brattleboro, VT). The fluorescence light was
subsequently split by a 425 nm dichroic mirror to permit simultaneous
measurements of both 405 nm and 500 nm wavelengths through band-pass
filters, respectively, by use of two separate photomultiplier tubes.
The fluorescence ratio (405 nm/500 nm) was then used as an index of [Ca++]i.
The cell length was monitored simultaneously with indo-1 fluorescence
using red light (>620 nm) through the normal bright field illumination
optics of the microscope. The bright field image of the cell was
collected by an objective lens and first separated by a 580 nm
long-pass dichroic mirror (Omega Optical). This image was projected
onto a photodiode array (C6294-01, Hamamatsu Photonics, Hamamatsu,
Japan) scanned at every 5 msec.
Cell length and indo-1 fluorescence data were acquired by use of a
computer (Power Macintosh 8100/100AV, Apple Computer, Cupertino, CA)
with an A/D converter (MP-100A, BIOPAC Systems, Santa Barbara, CA) and
analyzed after the low-pass filtering (cutoff frequency of 25 Hz) and
averaging of 5 successive signals.
Drugs and chemicals.
The following drugs were used; SCH00013
(Zenyaku Kogyo Co. Ltd., Tokyo, Japan); (±)-bupranolol hydrochloride
(Kaken Pharmaceutical Co. Ltd., Tokyo, Japan); (-)-isoproterenol
hydrochloride, carbachol (carbamylcholine chloride), fetal bovine
serum, pluronic F-127 and protease (type XIV) (Sigma Chemical
Co., St. Louis, MO); collagenase (class II, Worthington Biochemical,
Freehold, NJ); EMD 57033 ((+)-5-[1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydro-6-quinolyl]-6-methyl-3,6-dihydro-2H-1,3,4-thiadiazin-2-one; E. Merck, Darmstadt, Germany); indo-1/AM (Dojindo Laboratories, Kumamoto, Japan).
Statistical analysis.
Experimental values are presented as
mean ± S.E.M. Statistical analysis of the data was performed by
one-way analysis of variance followed by application of the
Bonferroni/Dunn method. A value of P < .05 was considered to
indicate a statistically significant difference.
 |
Results |
Inotropic effects of SCH00013 on isolated dog and rabbit
ventricular muscles.
SCH00013 at concentrations of greater than
10
6 M elicited a positive inotropic effect
on isolated dog ventricular trabeculae in a concentration-dependent
manner (fig. 2A). The positive inotropic effect of SCH00013 at 10
4 M (the highest
concentration examined because the compound produced insoluble
precipitation at 3 × 10
4 M) was
43.3 ± 4.4% of ISOmax. Thus, the EC50
value of SCH00013 was approximately (1.60 ± 0.21) × 10
5 M or higher. The positive inotropic
effect of SCH00013 was not influenced by 3 × 10
7 M of bupranolol (fig. 2A). The
positive inotropic effect at 10
4 M and
EC50 value of SCH00013 in the presence of
bupranolol were 37.5 ± 3.9% of ISOmax and approximately
(1.47 ± 0.38) × 10
5 M, which did
not significantly differ from those in the absence of bupranolol.
SCH00013 did not affect the time course of isometric contractions in
dog ventricular trabeculae as shown in figure 2B.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of SCH00013 on force of contraction and the
time course of contraction in isolated dog ventricular trabeculae and
rabbit ventricular papillary muscles which were electrically stimulated
by square-wave pulses of 5 msec duration and a voltage ~20% above
the threshold at 0.5 Hz and 1.0 Hz, respectively, through bipolar
platinum electrodes. A and B, Concentration-response curves for the
positive inotropic effect (A) and the time course of contraction (B) in
dog ventricular trabeculae. The response to SCH00013 was determined in
the absence or presence of 3 × 10 7 M of
bupranolol. The positive inotropic response to SCH00013 in the presence
of bupranolol in B was not significantly different from the response in
its absence. Bupranolol was administered in the organ bath 30 min
before determination of the force of contraction and present throughout
the experiments. Basal force of contraction: 11.9 ± 3.0 mN/mm2 (n = 7) in the control group and
16.3 ± 2.3 mN/mm2 (n = 7) in the
bupranolol group; ISOmax: 23.6 ± 3.1 mN/mm2 in the
control group and 30.7 ± 4.3 mN/mm2 in the bupranolol
group. C and D, Concentration-response curves for the positive
inotropic effect (C) and the time course of contraction (D) in the
presence of 3 × 10 7 M bupranolol in
rabbit right ventricular papillary muscles. Basal force of contraction:
6.8 ± 1.2 mN/mm2 (n = 10);
ISOmax: 17.6 ± 1.7 mN/mm2; b: the base-line levels
before administration of SCH00013 were assigned to zero. Asterisks
indicate the threshold concentration (*P < .05 vs. the corresponding base-line values).
|
|
In isolated rabbit papillary muscles, SCH00013 elicited a positive
inotropic effect over an identical concentration range as seen in the
dog. At concentrations of greater than 10
6
M SCH00013 elicited a positive inotropic effect in a
concentration-dependent manner on isolated rabbit papillary muscles in
the presence of 3 × 10
7 M bupranolol
(fig. 2C). The positive inotropic effect of SCH00013 at
10
4 M was 29.4 ± 5.5% of ISOmax.
The EC50 value of SCH00013 was approximately (8.96 ± 2.36) × 10
6 M or higher.
SCH00013 prolonged the isometric contractions in rabbit papillary
muscles in the presence of bupranolol. The duration of contraction and
relaxation time were significantly increased, whereas time to peak
force was not affected (fig. 2D). Thus, SCH00013 prolonged the duration
of contraction, primarily by prolongation of relaxation time in the
rabbit papillary muscle.
Chronotropic effects of SCH00013 on isolated rabbit right
atria.
The effect of SCH00013 on the rate of beating in isolated
rabbit right atria is shown in table 1. SCH00013 (3 × 10
7 to 10
4
M) did not significantly alter the rate of beating.
View this table:
[in this window]
[in a new window]
|
TABLE 1
Effects of SCH00013 on rate of beating in isolated rabbit right atria
The maximal rate of beating in response to isoproterenol was 302.1 ± 7.7 beats/min (n = 7).
|
|
Effects of SCH00013 on cell shortening and
Ca++ transients in rabbit ventricular
cardiomyocytes.
Representative tracings of the effects of
elevation of extracellular Ca++ concentration
([Ca++]o),
isoproterenol, SCH00013 and EMD 57033 on cell shortening and indo-1
fluorescence ratio in indo-1 loaded rabbit ventricular cardiomyocytes
are shown in figures 3 and
4, respectively. Elevation of
[Ca++]o increased cell
shortening in a concentration-dependent manner in association with
increases in indo-1 fluorescence ratio (fig. 3A).
Ca++ transients were slightly abbreviated by an
elevation of [Ca++]o, but
the duration of cell shortening was scarcely affected (fig. 3A, i).
Isoproterenol, a beta adrenoceptor agonist, also exerted a
concentration-dependent positive inotropic effect, accompanied by a
pronounced increase in indo-1 fluorescence ratio (fig. 3B). Isoproterenol markedly abbreviated the duration of cell shortening and
indo-1 fluorescence ratio (fig. 3B, h). By contrast, SCH00013 and EMD
57033, Ca++ sensitizers, increased cell
shortening with little changes in the amplitude of indo-1 fluorescence
ratio (fig. 4, A and B). The time course of cell shortening and indo-1
fluorescence ratio was scarcely affected by SCH00013 (fig. 4A, h). The
diastolic cell length was affected less by SCH00013 than by EMD 57033:
the diastolic cell length was somewhat reduced by SCH00013 at
concentrations higher than 3 × 10
5 M
(fig. 4A), though not as strongly as with EMD 57033 (fig. 4B). On the
other hand, the positive inotropic effect of EMD 57033 was accompanied
by a striking reduction in diastolic cell length (fig. 4B). Moreover,
EMD 57033 prolonged the time course of cell shortening with little
changes in the time course of indo-1 fluorescence ratio (fig. 4B, g).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3.
Representative tracings of the effects of
[Ca++]o (A) and isoproterenol (B) on cell
shortening and Ca++ transients in indo-1 loaded rabbit
ventricular cardiomyocytes. A, The myocyte was exposed to increasing
concentrations of [Ca++]o that were indicated
by horizontal bars in upper panel. Top, continuous recordings of cell
length; bottom: cell length and indo-1 fluorescence ratio
simultaneously measured at times indicated by letters (a-h) below the
continuous tracings in upper panel; a, control before elevation of
[Ca++]o; h, after washout of high
[Ca++]o; i, amplitudes of tracings in a and g
have been adjusted electronically and superimposed to facilitate
comparison of their time courses; a-h in bottom are recorded at times
corresponding to a-h in top. B, The myocyte was exposed to increasing
concentrations of isoproterenol that are indicated by horizontal bars
in top; a, control before addition of isoproterenol; g, after washout
of isoproterenol; h, amplitudes of tracings in a and f have been
adjusted electronically and superimposed to facilitate comparison of
their time courses; a-g in bottom are recorded at times corresponding
to a-g in top.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 4.
Representative tracings of the effects of SCH00013
(A) and EMD 57033 (B) on cell shortening and Ca++
transients in indo-1 loaded rabbit ventricular cardiomyocytes. A, The
myocyte was exposed to increasing concentrations of SCH00013 that were
indicated by horizontal bars in upper panel; a, control before addition
of SCH00013; g, after washout of SCH00013; h, amplitudes of tracings in
a and f have been adjusted electronically and superimposed to
facilitate comparison of their time courses; a-g in bottom are
recorded at times corresponding to a-g in top. B, The myocyte was
exposed to increasing concentrations of EMD 57033 that were indicated
by horizontal bars in top; a, control before addition of EMD 57033; f,
after washout of EMD 57033; g, amplitudes of tracings in a and e have
been adjusted electronically and superimposed to facilitate comparison
of their time courses; a-f in bottom are recorded at times
corresponding to a-f in top.
|
|
The summarized data are presented in figure
5. Elevation of
[Ca++]o and isoproterenol
increased both systolic levels of cell length and fluorescence ratio in
a concentration-dependent manner (fig. 5, A and B). The systolic levels
of cell length and fluorescence ratio were increased by
[Ca++]o at 14.4 mM to
272.6 ± 39.9% and 206.7 ± 10.9% of the control values,
respectively. Isoproterenol at 3 × 10
8 M increased the systolic levels of
cell length to 241.5 ± 28.6% and fluorescence ratio to
227.9 ± 14.4% of the control values. In contrast to elevation of
[Ca++]o and
isoproterenol, neither SCH00013 nor EMD 57033 increased the systolic
level of fluorescence ratio, when these compounds increased systolic
cell shortening (fig. 5, C and D). The systolic cell shortening was
significantly increased to 152.1 ± 2.2% of the control value
with SCH00013 at 10
4 M without a
significant change in systolic level of fluorescence ratio (114.8 ± 6.7% of the control value; P > .05). The systolic cell
shortening was significantly increased by EMD 57033 at 3 × 10
6 M to 233.7 ± 16.4% of the
control value with no change in the systolic level of fluorescence
ratio (100.0 ± 8.5% of the control value; P > .05).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 5.
Effects of [Ca++]o (A),
isoproterenol (B), SCH00013 (C) and EMD 57033 (D) on systolic levels of
cell shortening and fluorescence ratio of indo-1 loaded in rabbit
ventricular cardiomyocytes. Only one concentration-response
relationship was determined in each cardiomyocyte. Diastolic cell
lengths and extents of shortening in the base line before respective
interventions: 138.2 ± 6.6 µm and 7.58 ± 0.94% in A
(n = 7); 140.8 ± 7.8 µm and 7.04 ± 0.55% in B (n = 7); 152.4 ± 7.9 µm and
7.73 ± 0.31% in C (n = 10); 140.3 ± 7.7 µm and 8.07 ± 0.93% in D (n = 7).
Numbers in parentheses in A and B indicate the number of myocytes at
highest concentrations, at which two myocytes, respectively, became
arrhythmic and were therefore deleted from the analysis. Asterisks
indicate the threshold concentration (*P < .05 vs. the corresponding control values).
|
|
Figure 6 shows the relationship between the systolic
levels of indo-1 fluorescence ratio and systolic cell shortening during exposure to increasing concentrations of
[Ca++]o, isoproterenol,
SCH00013 and EMD 57033. SCH00013 and EMD 57033 shifted the relationship
to the left as compared with those of elevation of
[Ca++]o and
isoproterenol. Isoproterenol at 10
9 M and
higher shifted the relationship to the right as compared with that of
elevation of [Ca++]o.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 6.
The relationship between the systolic levels of
cell length and fluorescence ratio during exposure to increasing
concentrations of [Ca++]o, isoproterenol,
SCH00013 and EMD 57033 in indo-1 loaded rabbit ventricular
cardiomyocytes. Data are taken from those in figure 5.
|
|
Effects of carbachol on the positive inotropic effect of
SCH00013.
Carbachol inhibits selectively the cAMP-dependent
positive inotropic effect of cardiotonic agents in mammalian
ventricular myocardium (Endoh, 1980
, 1987
). Therefore, we investigated
whether cAMP would be involved in the positive inotropic effect of
SCH00013 by use of carbachol in isolated dog and rabbit ventricular
muscles.
Carbachol (3 × 10
6 M) shifted the
concentration-response curves for SCH00013 to the right and downward,
but did not abolish the positive inotropic effect of SCH00013, as shown
in figure 7, A (dog) and B (rabbit). The
extent of inhibition induced by carbachol was more pronounced at higher
concentrations of SCH00013, indicating that the contribution of the
cAMP-dependent effect is increased when the concentration of SCH00013
increases. In the dog ventricular trabeculae, the response to SCH00013
at 10
4 M was decreased by carbachol from
37.5% to 15.7% of ISOmax (fig. 7A). In the rabbit papillary muscle,
the response to SCH00013 at 10
4 M was
decreased by carbachol from 29.4% to 12.5% of ISOmax (fig. 7B). It
was noted that the force of contraction in the presence of carbachol
was still significantly greater than the basal force in both species.
These results suggest a significant contribution of the cAMP-dependent
mechanism to the positive inotropic effect of SCH00013, namely at
higher concentrations.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 7.
Influence of carbachol on the positive inotropic
effect of SCH00013 in isolated dog ventricular trabeculae (A) and
rabbit right ventricular papillary muscles (B) which were electrically
stimulated by square-wave pulses of 5 msec duration and a voltage about
20% above the threshold at 0.5 Hz and 1.0 Hz, respectively, through
bipolar platinum electrodes. The response to SCH00013 was determined in
the presence of 3 × 10 7 M bupranolol.
Only one concentration-response curve was determined in each
preparation. The control concentration-response curves are the same as
those presented in figure 2; b: the base-line levels before
administration of SCH00013 were assigned to zero. In the carbachol
group, the basal force of contraction was 13.6 ± 4.2 mN/mm2 in the dog (n = 7) and 5.3 ± 1.7 mN/mm2 in the rabbit (n = 8).
ISOmax was 19.7 ± 3.4 mN/mm2 in the dog and 14.3 ± 3.1 mN/mm2 in the rabbit. Asterisks indicate the
threshold concentration (*P < .05 vs. the
corresponding base-line values).
|
|
Effects of SCH00013 on the positive inotropic effect of
isoproterenol.
The influence of SCH00013 on the
concentration-response curves for the positive inotropic effect of
isoproterenol in dog ventricular trabeculae and rabbit papillary
muscles is shown in figure 8. In both
species, SCH00013 at 3 × 10
6 M and
3 × 10
5 M elicited a positive
inotropic effect in a concentration-dependent manner (fig. 8, A and C).
The concentration-response curve for isoproterenol was determined in
the absence or in the presence of different concentrations of SCH00013.
In both species, the concentration-response curve for isoproterenol is
not affected by SCH00013 at 3 × 10
6
M, but it appears to be shifted to the left and upward by SCH00013 at
3 × 10
5 M (fig. 8, A and C). The
increase induced by SCH00013 was subtracted from the total increase
[(isoproterenol + SCH00013) minus SCH00013], and the
concentration-response curve for isoproterenol was constructed with the
remaining increase caused by isoproterenol expressed as 100% and
compared with the curve with isoproterenol alone: the
concentration-response curve for isoproterenol was shifted to the left
in a parallel manner in both species (fig. 8, B and D). In the dog
ventricular trabeculae, pD2 values for
isoproterenol in the presence of 3 × 10
6 M and 3 × 10
5 M SCH00013 were 7.70 and 8.26, respectively. The value in the presence of 3 × 10
5 M SCH00013 was significantly higher
than the control value of 7.53. In the rabbit papillary muscles, the
pD2 value in the presence of 3 × 10
5 M SCH00013 (8.94) was also
significantly greater than the control value (8.46).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 8.
Influence of SCH00013 on the positive inotropic
effect of isoproterenol in isolated dog ventricular trabeculae (A and
B) and rabbit ventricular papillary muscles (C and D) which were
electrically stimulated by square-wave pulses of 5 msec duration and a
voltage about 20% above the threshold at 0.5 Hz and 1.0 Hz,
respectively, through bipolar platinum electrodes. Only one
concentration-response curve for isoproterenol was determined in each
preparation. A and C, Concentration-response curves for isoproterenol
are constructed with isoproterenol alone (control, ), isoproterenol + 3 × 10 6 M SCH00013 ( ) and
isoproterenol + 3 × 10 5 M SCH00013
( ), respectively. B and D, Concentration-response curves for
isoproterenol alone or after subtraction of the increases in force
induced by SCH00013 (the increase elicited by isoproterenol was
assigned to 100%) are presented: isoproterenol alone ( ),
isoproterenol + 3 × 10 6 M SCH00013
minus SCH00013 ( ) and isoproterenol + 3 × 10 5 M SCH00013 minus SCH00013 ( ),
respectively; b: the base-line levels before administration of
isoproterenol. Basal force of contraction in A: 9.6 ± 2.8 mN/mm2 in control group (n = 7),
13.7 ± 2.3 mN/mm2 in group with 3 × 10 6 M SCH00013 (n = 7)
and 14.5 ± 3.1 mN/mm2 in group with 3 × 10 5 M SCH00013 (n = 7).
The corresponding ISOmax values were 16.1 ± 2.6, 18.4 ± 1.0 and 18.3 ± 2.9 mN/mm2 (n = 7 each), respectively. Basal force of contraction in C: 7.4 ± 1.2 mN/mm2 in control group (n = 5),
8.0 ± 2.0 mN/mm2 in group with 3 × 10 6 M SCH00013 (n = 5)
and 9.7 ± 2.5 mN/mm2 in group with 3 × 10 5 M SCH00013 (n = 4).
The corresponding ISOmax values were 37.0 ± 5.6, 25.4 ± 9.1 and 25.7 ± 6.0 mN/mm2 (n = 4 or
5), respectively. *P < .05 vs. the corresponding
control values.
|
|
 |
Discussion |
The pyridazinone derivative SCH00013 elicited a
concentration-dependent positive inotropic effect in isolated dog and
rabbit ventricular myocardium. The positive inotropic effect of
SCH00013 was not affected by bupranolol, a potent beta
adrenoceptor blocking agent, implying that the activation of
beta adrenoceptors is not involved in the positive inotropic
effect of the compound. The characteristic pharmacological profile of
SCH00013 is that it elicits a positive inotropic effect (fig. 2)
without chronotropic effect (table 1). The present findings indicate
that two mechanisms, the increase in Ca++
sensitivity of contractile proteins, which may be independent of cAMP
metabolism, and the cAMP-dependent regulation that may involve the
inhibition of cAMP PDE, contribute to the positive inotropic effect of
SCH00013.
An increase in myofibrillar Ca++
sensitivity by SCH00013.
In isolated rabbit ventricular
cardiomyocytes loaded with indo-1/AM, elevation of
[Ca++]o and isoproterenol
increased the extent of cell shortening in association with an increase
in the amplitude of Ca++ transients in a
concentration-dependent manner (fig. 3). By contrast, EMD 57033, a
prototype Ca++ sensitizer (Solaro et
al., 1993
), and SCH00013 increased the cell shortening with little
increase in the amplitude of Ca++ transients
(fig. 4). The experimental system used to detect the inotropic effect
of drugs is not ideal because the cell is not stretched to the optimal
length in Frank-Starling mechanism. Nevertheless, the relationship
between the peak fluorescence ratio and the systolic cell shortening
was shifted to the right by isoproterenol and to the left by EMD 57033, an indication that the experimental system reflects well the
qualitative modulation of myofibrillar Ca++
sensitivity (fig. 6) as also shown in the previous study (Fujita and
Endoh, 1996
). While the mechanism for the increase in myofibrillar Ca++ sensitivity induced by SCH00013 is not
clear, the differences in the effects of the compound from those of EMD
57033 are evident from the present findings as follows: 1) the positive
inotropic effect of SCH00013 is more moderate than that of EMD 57033;
2) SCH00013 affected the time course of neither
Ca++ transients nor cell shortening, while EMD
57033 increased the duration of cell shortening without affecting the
duration of Ca++ transients; and 3) SCH00013 had
only a slight effect on the diastolic cell length, while EMD 57033 decreased markedly the diastolic level of cell length at concentrations
of 10
6 M and higher (fig. 4). The last
difference is considered to be of importance with respect to the
potential risk of diastolic dysfunction that might occur in clinical
application of certain Ca++ sensitizers
especially to the patients with severe congestive heart failure (Hajjar
et al., 1997
). Although Ca++
sensitizers have a favorable effect on myocardial energy consumption, impairment of cardiac relaxation is a possible adverse effect of
Ca++ sensitizers (Higashiyama et al,
1995
; Nielsen-Kudsk and Aldershvile, 1995
; Hajjar et al.,
1997
). In fact, EMD 57033 reduced diastolic cell length and prolonged
relaxation time of cell shortening with no changes in
Ca++ transients in the rabbit ventricular
cardiomyocyte (fig. 4B).
cAMP-mediated effects of SCH00013.
The absence of effects of
SCH00013 to shorten the diastolic cell length may be partly due to
contribution of cAMP-mediated effect of SCH00013. The following pieces
of evidence indicate the involvement of cAMP in the effect of SCH00013:
1) the positive inotropic effect of SCH00013 was suppressed by
carbachol (fig. 7); and 2) SCH00013 at 3 × 10
5 M shifted the concentration-response
curve for isoproterenol to the left (fig. 8). A muscarinic receptor
antagonist, carbachol, does not affect the basal force of contraction
and cAMP-independent positive inotropic effect of agents such as
ouabain, elevation of
[Ca++]o and
alpha adrenoceptor agonists, but suppresses selectively the
cAMP-mediated effect of agents such as isoproterenol, papaverine and
theophylline in dog ventricular myocardium (Endoh, 1979
, 1980
, 1987
).
Carbachol inhibited the positive inotropic effect of SCH00013 by about
50% in both dog and rabbit ventricular muscle (fig. 7). These results
imply that the positive inotropic effect of SCH00013 namely at higher
concentrations may be due to an approximately equal contribution of
cAMP-mediated and cAMP-independent mechanism (an increase in
myofibrillar Ca++ sensitivity).
The inhibitory action of SCH00013 on the cAMP PDE may be responsible
for the cAMP-mediated regulation because SCH00013 (3 × 10
5 M) enhanced the positive inotropic
effect of isoproterenol (fig. 8). SCH00013 inhibits the activity of PDE
III isolated from guinea pig heart with an IC50
value of 7.3 × 10
5 M (unpublished
data). It is noteworthy, however, that in the isolated rabbit papillary
muscle SCH00013 at 3 × 10
6 M that
produced a definite positive inotropic effect (fig. 2) did not enhance
the effect of isoproterenol and first at 3 × 10
5 M it shifted the
concentration-response curve for isoproterenol to the left (fig. 8).
These observations indicate that SCH00013 is not potent as a cAMP PDE
inhibitor and the magnitude of contribution of cAMP-independent effect
namely at low concentrations may be greater than that of the
cAMP-dependent effect. The findings that carbachol suppressed the
positive inotropic effect of SCH00013 more markedly over higher than
lower concentration range (fig. 7) support a greater contribution of
cAMP at higher concentrations. SCH00013 was slightly less potent in
single myocytes (figs. 4 and 5) than in isolated papillary muscles
(fig. 2) of the rabbit in inducing the positive inotropic effect. This
may be mainly due to the difference in experimental conditions:
papillary muscles contract in an isometric manner at 1 Hz being
stretched to near Lmax at 37°C, while single myocytes contract in an
isotonic (auxotonic) manner from the slack length at room temperature.
Overall cardiac effects of SCH00013.
The duration of isometric
contractions of the muscle was not abbreviated, but was unchanged (dog)
or rather prolonged (rabbit) by SCH00013 (fig. 2). These findings
contradict to the contribution of cAMP-mediated effect to the
myocardial contractility in general, which is characterized by a
pronounced abbreviation of duration of contraction and acceleration of
relaxation (Endoh and Blinks, 1988
; isoproterenol in fig. 3). This may
be partly due to a balance between cAMP-mediated and
Ca++ sensitizing action.
Another characteristic property of SCH00013 is a lack of positive
chronotropic effect, which is due to screening of the compound that has
no or less positive chronotropic action. However, the cellular
mechanism by which no positive chronotropic effect of the agent that
facilitates a cAMP-mediated process can occur remains obscure. In this
respect, the profile of SCH00013 has a close resemblance to that of
vesnarinone in which the cAMP-mediated positive chronotropic effect is
counteracted by its effect to decrease the K+
conductance in myocardial cell membrane (Iijima and Taira, 1987
). The
observations that SCH00013 prolonged the duration of contraction in
isolated rabbit papillary muscles (fig. 2) support such a possibility that the compound prolongs the duration of action potential by inhibition of K+ channels. No matter how the
mechanism involved, the lack of positive chronotropic effect may be
beneficial for the application to the patients with congestive heart
failure because of the avoidance of unnecessary increase in oxygen
consumption, which is an important determinant to exacerbate the heart
failure syndrome, and because of disappearance or inversion of the
positive force-frequency relationship in these patients (Mulieri
et al., 1992
; Schwinger et al., 1994
).
In conclusion, SCH00013 produces a positive inotropic effect
predominantly through myofibrillar Ca++
sensitization with a moderate contribution of cAMP-dependent mechanism.
It does not alter the heart rate. These observations imply that
SCH00013 may have potential as a cardiotonic agent with novel
mechanisms of action for the treatment of congestive heart failure.
We thank Drs. S. Fujita, T. Watanabe, H.-T. Yang for sharing
preparation of rabbit ventricular cardiomyocytes in some of the present
experiments. We are also grateful to Zenyaku Kogyo Co. Ltd. (Tokyo,
Japan) for providing us the opportunity to study the mechanism of
action of SCH00013 in the early stage of its development, to E. Merck
(Darmstadt, Germany) for providing EMD 57033 and to Kaken
Pharmaceutical Co. Ltd. (Tokyo, Japan) for providing (±)-bupranolol
hydrochloride.
Accepted for publication June 2, 1998.
Received for publication March 6, 1998.